Skip to main content
SpringerLink
Log in

Pharmacokinetics of [4-14C] Mofebutazone after oral administration in man

  • Original Papers
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics of mofebutazone was investigated in man after oral administration of [4-14C] mofebutazone in suspension form (7 mg/kg body weight). The blood concentration / time course was found to fit a two compartment open model with first order absorption (ka=10.1 h−1) where elimination (kel=0.304 h−1) occurs only from compartment 1. The maximum concentration was reached after 0.3 h in compartment 1 and after 2 h in compartment 2. Mofebutazone was found to be excreted almost exclusively via the kidney; 97% of the administered dose was found in urine already at 72 h. Excretion takes place very rapidly; 24% of the dose was excreted in 1.5 h and 45% in 3 h. 92% of the mofebutazone excreted was the conjugated form. Two glucuronides were detected in the 24 h urine; one of these seemed to be identical to a glucuronide fractionated from the urine of rat. The renal clearance of mofebutazone in man was found to be 3.38 1/h. The almost complete recovery of mofebutazone in the urine indicates that after oral administration, this drug has a very high bioavailability via the oral route.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krohs W. (1965): Pyrazole Derivatives in ‘Analgetics’, edited by G. deStevens, Academic Press, New York, pp. 331–403.

    Google Scholar 

  2. Larsen V., Dredahl E. (1966): The embryotoxic effect on rabbits of monophenyl butazone (Monazan) compared with phenylbutazone and thalidomide. Acta Pharmacol. Toxicol.,24, 443–455.

    CAS  Google Scholar 

  3. Thune S. (1967): Comparison of phenyl- and monophenylbutazone (Mobutazon), especially in respect to the incidence of side effects. A double blind study. Acta Rheumatolog. Scand.,13, 63–80.

    CAS  Google Scholar 

  4. Woodbury J.F.L., Turner W.A., Tiongson R. (1969): Rheumatoid arthritis: comparison of treatment with monophenylbutazone and phenylbutazone. Can. Med. Assoc. J.101, 801–803.

    Google Scholar 

  5. Scarselli V. (1959): Tossicita e cinetica dell eliminazione del 2-fenil, 3,5-diossi, 4-n-butil, pirazolidina comparativamente a quelle del 1,2-difenil-derivato. II Farmaco, Ed. Sci.,14, 347–351.

    CAS  Google Scholar 

  6. Holmen-Christensen H. (1967): Identification and UV spectrophotometric determination of phenylbutazone analogues from thinlayer chromatograms, in ‘Scientiae Pharmaceuticae’ Vol. II (Proceedings of the 25th Congress of Pharmaceutical Sciences, Prague, 1965), edited by O. Hanc and J. Hubik. Butterworths, London, pp. 152–160.

    Google Scholar 

  7. Bass V.-M., Mrongovius R.I. and Schulte K.E. (1980): Disposition of 4-14C mofebutazone in the rat. Eur. J. Drug Metabol. Pharmacok.5, 201–206.

    Article  CAS  Google Scholar 

  8. Mrongovius, R., Bass V.-M., and Schulte K.E. (1982): Anti-inflamtory activity and disposition in the rat of mofebutazone and two degradation products. Eur. J. Med. Chem.17, 275–279.

    CAS  Google Scholar 

  9. Miller J.P. (1971): Health Hazards of Radioactive Pharmaceuticals, in International Encyclopedia of Pharmacology and Therapeutics, Ed.: Peters G., Section 78, Radionucleotides in Pharmacology, Section Ed.: Y. Cohen, Vol. II, pp. 883–901.

  10. Wagner J.G. (1975): Fundamentals of Clinical Pharmacokinetics, pp. 102–106, the Hamilton Press, Inc., Hamilton, Illinois.

    Google Scholar 

  11. Dieterle W., Faigle J.W., Früh F., Mory H., Theobald W., Alt K.O., and W. Richter (1976): Metabolism of phenylbutazone in man. Arzneim.-Forsch.26, 572–577.

    CAS  Google Scholar 

  12. Leber H.W., Härders A., and Schütterle G. (1972): Untersuchungen zum Einfluss der Urämie auf die Metabolisierung von Phenylbutazon und Aminophenazon beim Menschen. Klin. Wschr.50, 1092–1096.

    Article  CAS  PubMed  Google Scholar 

  13. Rowland M., and Riegelman S. (1968): Pharmacokinetics of acetylsalicylic acid after intraveneous administration to rats. J. Pharm. Sci.57, 1313–1319.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Research Centre, Pharmaceutical Sciences Department, Dokki, Cairo, Egypt

    M. A. Kassem

  2. Institut für Pharmazeutische Chemie der Universität Münster, Hittorfstrasse 58-62, D-4400, Münster, F.R.G.

    K. E. Schulte

Authors
  1. M. A. Kassem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. E. Schulte
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kassem, M.A., Schulte, K.E. Pharmacokinetics of [4-14C] Mofebutazone after oral administration in man. European Journal of Drug Metabolism and Pharmacokinetics 9, 223–227 (1984). https://doi.org/10.1007/BF03189645

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189645

Key words

Search

Navigation